TRILLIUM THERAPEUTICS INC. Operating Income
TRILLIUM THERAPEUTICS INC. reported Operating Income of -$19.45 million for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-12.
Discontinued › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2021-11-12
- TRILLIUM THERAPEUTICS INC. operating income (loss) for the quarter ending 2021-09-30 was -$19.45M.
- TRILLIUM THERAPEUTICS INC. operating income (loss) for the quarter ending 2021-06-30 was -$18.67M.
- TRILLIUM THERAPEUTICS INC. operating income (loss) for the quarter ending 2021-03-31 was -$11.31M.
- TRILLIUM THERAPEUTICS INC. operating income (loss) for the quarter ending 2020-12-31 was -$8.04M.
- TRILLIUM THERAPEUTICS INC. operating income (loss) for fiscal 2020 was -$61.45M.
- TRILLIUM THERAPEUTICS INC. operating income (loss) for fiscal 2019 was -$32.29M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 6 month | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month |
|---|---|---|---|---|
| 2021-09-30 | -$19.45M 10-Q · filed 2021-11-12 | -$38.12M derived: sum of 2 quarters · filed 2021-11-12 | -$49.43M 10-Q · filed 2021-11-12 | -$57.47M derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-06-30 | -$18.67M 10-Q · filed 2021-08-13 | -$29.98M 10-Q · filed 2021-08-13 | -$38.02M derived: sum of 3 quarters · filed 2021-08-13 | -$51.02M derived: sum of 4 quarters · filed 2021-11-12 |
| 2021-03-31 | -$11.31M 10-Q · filed 2021-05-07 | -$19.36M derived: sum of 2 quarters · filed 2021-05-07 | -$32.35M derived: sum of 3 quarters · filed 2021-11-12 | -$56.11M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-12-31 | -$8.04M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | -$21.04M derived: sum of 2 quarters · filed 2021-11-12 | -$44.79M derived: sum of 3 quarters · filed 2021-11-12 | -$61.45M 10-K · filed 2021-03-18 |
| 2020-09-30 | -$12.99M 10-Q · filed 2021-11-12 | -$36.75M derived: sum of 2 quarters · filed 2021-11-12 | -$53.41M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$23.76M 10-Q · filed 2021-08-13 | -$40.42M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | -$16.66M 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | -$32.29M 10-K · filed 2021-03-18 |